{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:19:15Z","timestamp":1787750355620,"version":"build-2784847793"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>Janus kinases (JAKs) are a family of intracellular, non-receptor tyrosine kinases that play a crucial role in the JAK signaling pathway involved in the inflammatory process. Over the years, this pathway has garnered significant interest among researchers, leading to the development of various therapeutic agents aimed at blocking the pathway, thereby contributing to remarkable progress in the management of inflammatory diseases across multiple medical specialties. Although the use of JAK inhibitors in ophthalmology is still limited, evidence is gradually emerging on their role in managing uveitis and scleritis. One such agent is tofacitinib, a small-molecule pan-JAK inhibitor. Its therapeutic profile differs from that of biologics due to its partial and reversible inhibition of cytokines. Additionally, owing to its smaller molecular size, the drug is available in an oral formulation. In recent years, there has been a growing interest in JAK inhibitors, particularly tofacitinib, as a potential therapeutic option for refractory uveitis and scleritis in both adult and pediatric populations. Tofacitinib, either as monotherapy or in combination, has shown effectiveness in managing various uveitis cases that were unresponsive to conventional immunosuppressive therapies. It has also been explored in treatment-resistant scleritis. However, concerns persist regarding the potential adverse effects of tofacitinib, including cardiovascular events, thromboembolism, malignancies, and infections. This review aims to provide a comprehensive update on the role of tofacitinib in ocular inflammation, with particular emphasis on its clinical efficacy, safety profile, and the emerging literature surrounding its risks and side effects.<\/jats:p>","DOI":"10.4103\/ojo.ojo_425_25","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T02:00:15Z","timestamp":1782266415000},"page":"190-199","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Tofacitinib in uveitis and scleritis"],"prefix":"10.4103","volume":"19","author":[{"given":"Parthopratim","family":"Dutta Majumder","sequence":"first","affiliation":[{"name":"Department of Uvea and Intraocular Inflammation, Sankara Nethralaya, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fathima","family":"Fahima","sequence":"additional","affiliation":[{"name":"Department of Uvea and Intraocular Inflammation, Sankara Nethralaya, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakshita Deepak","family":"Kene","sequence":"additional","affiliation":[{"name":"Department of Uvea and Intraocular Inflammation, Sankara Nethralaya, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richa","family":"Pyare","sequence":"additional","affiliation":[{"name":"Shroff Eye Centre, Uvea Services, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyotirmay","family":"Biswas","sequence":"additional","affiliation":[{"name":"Department of Uveitis and Ocular Pathology, Sankara Nethralaya, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"R1-20260624","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway","volume":"27","author":"Morris","year":"2018","journal-title":"Protein Sci"},{"key":"R2-20260624","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.immuni.2008.03.002","article-title":"Cytokine signaling modules in inflammatory responses","volume":"28","author":"O'Shea","year":"2008","journal-title":"Immunity"},{"key":"R3-20260624","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.phrs.2019.03.006","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors","volume":"144","author":"Roskoski","year":"2019","journal-title":"Pharmacol Res"},{"key":"R5-20260624","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1126\/science.270.5237.797","article-title":"Mutation of Jak3 in a patient with SCID: Essential role of Jak3 in lymphoid development","volume":"270","author":"Russell","year":"1995","journal-title":"Science"},{"issue":"Suppl 2","key":"R6-20260624","doi-asserted-by":"crossref","first-page":"i111","DOI":"10.1136\/annrheumdis-2012-202576","article-title":"Janus kinase inhibitors in autoimmune diseases","volume":"72","author":"O'Shea","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R7-20260624","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40259-019-00333-w","article-title":"Selective JAKinibs: Prospects in inflammatory and autoimmune diseases","volume":"33","author":"Virtanen","year":"2019","journal-title":"BioDrugs"},{"key":"R8-20260624","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1124\/dmd.113.054940","article-title":"The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans","volume":"42","author":"Dowty","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"R10-20260624","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/0091270008330982","article-title":"Effect of CP-690,550, an orally active janus kinase inhibitor, on renal function in healthy adult volunteers","volume":"49","author":"Lawendy","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"R11-20260624","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.gastrohep.2020.04.012","article-title":"Pharmacology and safety of tofacitinib in ulcerative colitis","volume":"44","author":"L\u00f3pez-Sanrom\u00e1n","year":"2021","journal-title":"Gastroenterol Hepatol"},{"key":"R13-20260624","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/17425255.2024.2373092","article-title":"Pharmacokinetic review of Janus kinase inhibitors and its clinical implications for the management of rheumatoid arthritis","volume":"20","author":"Chandrashekara","year":"2024","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R14-20260624","first-page":"403452","article-title":"Tofacitinib citrate for ulcerative keratitis in a patient with rheumatoid arthritis","author":"Meadow","year":"2014","journal-title":"Case Rep Rheumatol 2014"},{"key":"R15-20260624","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ajoc.2018.12.001","article-title":"Tofacitinib for refractory uveitis and scleritis","volume":"13","author":"Paley","year":"2019","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R16-20260624","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1080\/09273948.2019.1605453","article-title":"Effect of Janus kinase inhibitor treatment on anterior uveitis and associated macular edema in an adult patient with juvenile idiopathic arthritis","volume":"27","author":"Bauermann","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"R17-20260624","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s10067-019-04875-w","article-title":"JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis","volume":"39","author":"Miserocchi","year":"2020","journal-title":"Clin Rheumatol"},{"key":"R18-20260624","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1080\/09273948.2022.2113805","article-title":"Tofacitinib in scleritis: A case series","volume":"32","author":"Pyare","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"key":"R19-20260624","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.4103\/ijo.IJO_998_20","article-title":"Tofacitinib in Vogt-Koyanagi-Harada disease","volume":"68","author":"Dutta Majumder","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"R20-20260624","doi-asserted-by":"crossref","first-page":"225","DOI":"10.55563\/clinexprheumatol\/3gymd4","article-title":"Resolution of ocular and mediastinal sarcoidosis after Janus kinase inhibitor therapy for concomitant rheumatoid arthritis","volume":"39","author":"Sejournet","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"R21-20260624","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.4103\/ijo.IJO_534_20","article-title":"Tofacitinib in recalcitrant scleritis: First case report from India","volume":"68","author":"Pyare","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"R22-20260624","first-page":"6201887","article-title":"A case of SAPHO syndrome complicated by uveitis with good response to both TNF inhibitor and JAKinib","author":"Baisya","year":"2023","journal-title":"Case Rep Rheumatol 2023"},{"key":"R23-20260624","doi-asserted-by":"crossref","first-page":"1759720X221093211","DOI":"10.1177\/1759720X221093211","article-title":"Clinical and immunological study of tofacitinib and baricitinib in refractory blau syndrome: Case report and literature review","volume":"14","author":"\u00c1lvarez-Reguera","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"R24-20260624","doi-asserted-by":"crossref","first-page":"e29189","DOI":"10.1097\/MD.0000000000029189","article-title":"Extended-release tofacitinib for refractory Beh\u00e7et disease: A case report","volume":"101","author":"Wang","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"R25-20260624","doi-asserted-by":"crossref","first-page":"784860","DOI":"10.3389\/fphar.2021.784860","article-title":"Case report: A promising treatment strategy for noninfectious uveitis","volume":"12","author":"Liu","year":"2021","journal-title":"Front Pharmacol"},{"key":"R26-20260624","first-page":"8294560","article-title":"New potential weapons for refractory scleritis in the era of targeted therapy","author":"Fabiani","year":"2020","journal-title":"Mediators Inflamm 2020"},{"key":"R27-20260624","doi-asserted-by":"crossref","first-page":"981502","DOI":"10.3389\/fimmu.2022.981502","article-title":"Case report: Refractory intestinal Beh\u00e7et's syndrome successfully treated with tofacitinib: A report of four cases","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Immunol"},{"key":"R28-20260624","doi-asserted-by":"crossref","first-page":"367","DOI":"10.31138\/mjr.20230828.ti","article-title":"Tofacitinib in refractory scleritis: A case series","volume":"34","author":"Dey","year":"2023","journal-title":"Mediterr J Rheumatol"},{"key":"R29-20260624","doi-asserted-by":"crossref","first-page":"1439338","DOI":"10.3389\/fmed.2024.1439338","article-title":"Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: A prospective cohort study from the international AIDA network registries","volume":"11","author":"Vitale","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"R30-20260624","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1080\/09273948.2024.2323671","article-title":"Tofacitinib for refractory uveitis and scleritis in children: A case series","volume":"32","author":"Dutta Majumder","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"key":"R31-20260624","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00431-023-05204-9","article-title":"Management of Blau syndrome: Review and proposal of a treatment algorithm","volume":"183","author":"Lassoued Ferjani","year":"2024","journal-title":"Eur J Pediatr"},{"key":"R32-20260624","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/gene.2014.64","article-title":"Activation of the JAK\/STAT pathway in Behcet's disease","volume":"16","author":"Tulunay","year":"2015","journal-title":"Genes Immun"},{"key":"R33-20260624","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1186\/s13063-021-05651-5","article-title":"Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: Study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT)","volume":"22","author":"Ramanan","year":"2021","journal-title":"Trials"},{"key":"R34-20260624","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/annrheumdis-2024-eular.5105","article-title":"Op0101 effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis associated uveitis or chronic anterior antinuclear antibody positive uveitis in children","volume":"83","author":"Ramanan","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R35-20260624","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1080\/09273948.2022.2069128","article-title":"Beneficial effect of upadacitinib in an adult patient with juvenile idiopathic arthritis-associated uveitis after unsatisfactory response to tofacitinib: A case report","volume":"31","author":"Baquet-Walscheid","year":"2023","journal-title":"Ocul Immunol Inflamm"},{"key":"R36-20260624","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): A phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"key":"R37-20260624","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"R38-20260624","doi-asserted-by":"crossref","first-page":"e002236","DOI":"10.1136\/rmdopen-2022-002236","article-title":"Waiting for JAK inhibitor safety data","volume":"8","author":"Kragstrup","year":"2022","journal-title":"RMD Open"},{"key":"R39-20260624","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/art.42846","article-title":"Risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors in cardiovascular risk-enriched rheumatoid arthritis patients","volume":"76","author":"Charles-Schoeman","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"R40-20260624","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41584-022-00767-7","article-title":"Oral surveillance and JAK inhibitor safety: The theory of relativity","volume":"18","author":"Winthrop","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"R41-20260624","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","article-title":"Tofacitinib and risk of cardiovascular outcomes: Results from the safety of TofAcitinib in routine care patients with rheumatoid arthritis (STAR-RA) study","volume":"81","author":"Khosrow-Khavar","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R42-20260624","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12348-023-00359-w","article-title":"Branch retinal vein occlusion in a case of recalcitrant diffuse anterior scleritis treated with tofacitinib","volume":"13","author":"Manoharan","year":"2023","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"R43-20260624","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.3390\/cancers15082197","article-title":"Cancer risk in patients treated with the JAK inhibitor tofacitinib: Systematic review and meta-analysis","volume":"15","author":"Bezzio","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R44-20260624","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/1744666X.2022.2014323","article-title":"The infection risks of JAK inhibition","volume":"18","author":"Adas","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"R45-20260624","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","article-title":"Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R46-20260624","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","article-title":"Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R47-20260624","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jiac.2017.03.002","article-title":"Cytomegalovirus retinitis followed by immune recovery uveitis in an elderly patient with rheumatoid arthritis undergoing administration of methotrexate and tofacitinib combination therapy","volume":"23","author":"Yanagisawa","year":"2017","journal-title":"J Infect Chemother"},{"key":"R48-20260624","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1093\/rheumatology\/kez681","article-title":"Tofacitinib-associated cytomegalovirus retinitis","volume":"59","author":"Cugley","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R49-20260624","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3899\/jrheum.210257","article-title":"Screening for Hepatitis B virus prior to initiating tocilizumab and tofacitinib in patients with rheumatic diseases: A cross-sectional study","volume":"49","author":"Mohareb","year":"2022","journal-title":"J Rheumatol"},{"key":"R50-20260624","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2021-11-4","article-title":"Tofacitinib and newer JAK inhibitors in inflammatory bowel disease-where we are and where we are going","volume":"11","author":"Liu","year":"2022","journal-title":"Drugs Context"},{"key":"R51-20260624","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","article-title":"Current and future status of JAK inhibitors","volume":"398","author":"McLornan","year":"2021","journal-title":"Lancet"},{"key":"R52-20260624","doi-asserted-by":"crossref","first-page":"13467","DOI":"10.12998\/wjcc.v10.i36.13467","article-title":"Precautions before starting tofacitinib in persons with rheumatoid arthritis","volume":"10","author":"Swarnakar","year":"2022","journal-title":"World J Clin Cases"},{"key":"R53-20260624","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: A consensus statement","volume":"80","author":"Nash","year":"2021","journal-title":"Ann Rheum Dis"}],"container-title":["Oman Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ojo.ojo_425_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:26:49Z","timestamp":1787747209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ojo.ojo_425_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ojo.ojo_425_25","relation":{},"ISSN":["0974-620X","0974-7842"],"issn-type":[{"value":"0974-620X","type":"print"},{"value":"0974-7842","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2025-10-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}